Saudi German Health 2021 profit slumps 79% to SAR 17.2 mln, turns to SAR 18.4 mln loss in Q4

Saudi German Health 2021 profit slumps 79% to SAR 17.2 mln, turns to SAR 18.4 mln loss in Q4

31/03/2022 Argaam Exclusive

View other reports

Middle East Healthcare Co.’s (Saudi German Health) net profit after Zakat and tax plunged 79% to SAR 17.2 million in 2021, from SAR 82 million in the previous year, as re-branding led to higher selling and marketing expenses.



Financials (M)

Item 2020 2021 Change‬
Revenues 1,750.59 1,872.62 7.0 %
Gross Income 578.37 608.18 5.2 %
Operating Income 107.41 40.50 (62.3 %)
Net Income 81.99 17.20 (79.0 %)
Average Shares 92.04 92.04 -
EPS (Riyals) 0.89 0.19 (79.0 %)

The group also noted an increase in consultancy expenses due to cost optimization project, and higher financial costs and accrual of Zakat.

 

Saudi German Health swung to a net loss after Zakat and tax of SAR 18.4 million in Q4 2021, from a profit of SAR 9.5 million in Q4 2020.

 

On a sequential basis, the firm posted a loss versus a profit of SAR 14.35 million in Q3 2021.



Current Quarter Comparison (M)

Compared With The
Item Q4 2020 Q4 2021 Change‬
Revenues 448.89 498.95 11.2 %
Gross Income 139.12 160.11 15.1 %
Operating Income 17.20 (7.03) (140.9 %)
Net Income 9.54 (18.39) (292.8 %)
Average Shares 92.04 92.04 -
EPS (Riyals) 0.10 (0.20) (292.8 %)

Shareholders’ equity, after minority interest, increased 2.1% year-on-year to SAR 1.257 billion in 2021.



Financial results (Million)

Period Revenues Change Gross Income Change Net Income Change EPS(Riyal)
Q1 2012 - - - - - - -
Q2 2012 - - - - - - -
Q3 2012 - - - - - - -
Q4 2012 - - - - - - -
Q1 2013 - - - - - - -
Q2 2013 - - - - - - -
Q3 2013 - - - - - - -
Q4 2013 - - - - - - -
Q1 2014 359.18 - 199.49 - 80.16 - 0.87
Q2 2014 347.08 - 185.78 - 92.80 - 1.01
Q3 2014 323.16 - 174.49 - 74.36 - 0.81
Q4 2014 369.34 - 190.01 - 84.64 - 0.92
Q1 2015 391.64 9.0 % 208.99 4.8 % 105.39 31.5 % 1.15
Q2 2015 372.00 7.2 % 203.88 9.7 % 91.79 (1.1 %) 1.00
Q3 2015 352.20 9.0 % 183.23 5.0 % 90.75 22.0 % 0.99
Q4 2015 418.69 13.4 % 214.04 12.6 % 102.32 20.9 % 1.11
Q1 2016 421.52 7.6 % 216.62 3.7 % 104.20 (1.1 %) 1.13
Q2 2016 410.07 10.2 % 212.49 4.2 % 74.07 (19.3 %) 0.80
Q3 2016 379.09 7.6 % 199.40 8.8 % 99.64 9.8 % 1.08
Q4 2016 404.96 (3.3 %) 199.88 (6.6 %) 84.73 (17.2 %) 0.92
Q1 2017 393.53 (6.6 %) 180.47 (16.7 %) 109.97 5.5 % 1.19
Q2 2017 351.28 (14.3 %) 138.63 (34.8 %) 61.95 (16.4 %) 0.67
Q3 2017 352.98 (6.9 %) 133.30 (33.1 %) 64.88 (34.9 %) 0.70
Q4 2017 364.60 (10.0 %) 145.47 (27.2 %) 82.69 (2.4 %) 0.90
Q1 2018 395.11 0.4 % 160.42 (11.1 %) 87.13 (20.8 %) 0.95
Q2 2018 346.13 (1.5 %) 116.91 (15.7 %) 34.27 (44.7 %) 0.37
Q3 2018 338.77 (4.0 %) 111.87 (16.1 %) 20.16 (68.9 %) 0.22
Q4 2018 310.68 (14.8 %) 111.56 (23.3 %) 30.69 (62.9 %) 0.33
Q1 2019 350.18 (11.4 %) 101.63 (36.6 %) 14.59 (83.3 %) 0.16
Q2 2019 353.20 2.0 % 102.76 (12.1 %) 12.28 (64.2 %) 0.13
Q3 2019 386.76 14.2 % 119.96 7.2 % 33.23 64.8 % 0.36
Q4 2019 406.51 30.8 % 148.59 33.2 % 37.47 22.1 % 0.41
Q1 2020 436.31 24.6 % 146.86 44.5 % 21.18 45.2 % 0.23
Q2 2020 373.26 5.7 % 120.49 17.3 % 16.35 33.2 % 0.18
Q3 2020 492.13 27.2 % 171.91 43.3 % 34.91 5.1 % 0.38
Q4 2020 448.89 10.4 % 139.12 (6.4 %) 9.54 (74.5 %) 0.10
Q1 2021 418.37 (4.1 %) 123.16 (16.1 %) 12.10 (42.9 %) 0.13
Q2 2021 456.57 22.3 % 152.64 26.7 % 9.14 (44.1 %) 0.10
Q3 2021 498.73 1.3 % 172.27 0.2 % 14.35 (58.9 %) 0.16
Q4 2021 498.95 11.2 % 160.11 15.1 % (18.39) (292.8 %) (0.20)
2021 1,872.62 7.0 % 608.18 5.2 % 17.20 (79.0 %) 0.19

Profitability

Period Gross Margin OIBDA Margin Net Margin Before Unusual Items
Q1 2012 - - -
Q2 2012 - - -
Q3 2012 - - -
Q4 2012 - - -
Q1 2013 - - -
Q2 2013 - - -
Q3 2013 - - -
Q4 2013 - - -
Q1 2014 - - -
Q2 2014 - - -
Q3 2014 - - -
Q4 2014 53.60 % 25.57 % 23.73 %
Q1 2015 53.05 % 27.10 % 24.96 %
Q2 2015 53.39 % 26.84 % 24.46 %
Q3 2015 52.93 % 27.56 % 25.09 %
Q4 2015 52.79 % 28.05 % 25.43 %
Q1 2016 52.27 % 27.77 % 24.87 %
Q2 2016 51.57 % 26.50 % 23.17 %
Q3 2016 51.71 % 26.41 % 23.34 %
Q4 2016 51.27 % 26.12 % 22.45 %
Q1 2017 49.90 % 26.91 % 23.20 %
Q2 2017 46.99 % 27.02 % 23.30 %
Q3 2017 43.41 % 25.39 % 21.40 %
Q4 2017 40.88 % 25.40 % 21.85 %
Q1 2018 39.47 % 24.17 % 20.26 %
Q2 2018 38.12 % 22.54 % 18.44 %
Q3 2018 37.01 % 20.57 % 15.52 %
Q4 2018 36.01 % 18.10 % 12.39 %
Q1 2019 32.84 % 13.74 % 7.41 %
Q2 2019 31.62 % 12.25 % 5.74 %
Q3 2019 31.12 % 12.85 % 6.48 %
Q4 2019 31.60 % 13.48 % 7.05 %
Q1 2020 32.74 % 13.41 % 7.09 %
Q2 2020 33.43 % 14.66 % 7.25 %
Q3 2020 34.41 % 14.80 % 6.90 %
Q4 2020 33.04 % 13.40 % 4.68 %
Q1 2021 32.01 % 12.65 % 3.20 %
Q2 2021 32.32 % 11.91 % 2.68 %
Q3 2021 32.22 % 11.12 % 1.77 %
Q4 2021 32.48 % 9.71 % 0.18 %
2021 32.48 % 9.71 % 0.18 %


Per Share Data (Riyal)

Compared With The
Period Shares Outstanding (M) EPS (Riyal) Adjusted EPS (Riyal) Book Value (BV)
Q1 2012 - - - -
Q2 2012 - - - -
Q3 2012 - - - -
Q4 2012 - - - -
Q1 2013 - - - -
Q2 2013 - - - -
Q3 2013 - - - -
Q4 2013 - - - -
Q1 2014 92.04 - - 10.70
Q2 2014 92.04 - - 11.69
Q3 2014 92.04 - - 12.48
Q4 2014 92.04 3.61 3.61 12.38
Q1 2015 92.04 3.88 3.88 13.50
Q2 2015 92.04 3.87 3.87 12.67
Q3 2015 92.04 4.05 4.05 13.63
Q4 2015 92.04 4.24 4.24 14.70
Q1 2016 92.04 4.23 4.23 16.39
Q2 2016 92.04 4.03 4.03 15.20
Q3 2016 92.04 4.13 4.13 16.43
Q4 2016 92.04 3.94 3.94 17.32
Q1 2017 92.04 4.00 4.00 18.46
Q2 2017 92.04 3.87 3.87 17.09
Q3 2017 92.04 3.49 3.49 17.74
Q4 2017 92.04 3.47 3.47 15.75
Q1 2018 92.04 3.22 3.22 16.69
Q2 2018 92.04 2.92 2.92 15.07
Q3 2018 92.04 2.44 2.44 15.29
Q4 2018 92.04 1.87 1.87 15.71
Q1 2019 92.04 1.08 1.08 15.87
Q2 2019 92.04 0.84 0.84 16.00
Q3 2019 92.04 0.99 0.99 16.36
Q4 2019 92.04 1.06 1.15 16.54
Q1 2020 92.04 1.13 1.22 16.77
Q2 2020 92.04 1.18 1.26 16.95
Q3 2020 92.04 1.19 1.28 17.33
Q4 2020 92.04 0.89 0.89 13.38
Q1 2021 92.04 0.79 0.60 13.51
Q2 2021 92.04 0.71 0.53 13.61
Q3 2021 92.04 0.49 0.35 13.77
Q4 2021 92.04 0.19 0.04 13.66

Multiple Ratios (End of Period Price)

Compared With The
Period P/E Adjusted P/E Price/book
Q1 2012 - - -
Q2 2012 - - -
Q3 2012 - - -
Q4 2012 - - -
Q1 2013 - - -
Q2 2013 - - -
Q3 2013 - - -
Q4 2013 - - -
Q1 2014 - - -
Q2 2014 - - -
Q3 2014 - - -
Q4 2014 - - -
Q1 2015 - - -
Q2 2015 - - -
Q3 2015 - - -
Q4 2015 - - -
Q1 2016 17.17 17.17 4.43
Q2 2016 17.16 17.16 4.56
Q3 2016 12.41 12.41 3.12
Q4 2016 18.62 18.62 4.23
Q1 2017 18.48 18.48 4.01
Q2 2017 19.45 19.45 4.41
Q3 2017 17.98 17.98 3.54
Q4 2017 15.52 15.52 3.42
Q1 2018 17.90 17.90 3.46
Q2 2018 20.02 20.02 3.88
Q3 2018 15.00 15.00 2.39
Q4 2018 17.34 17.34 2.07
Q1 2019 29.49 29.49 2.01
Q2 2019 32.63 32.63 1.72
Q3 2019 26.36 26.36 1.59
Q4 2019 28.02 25.89 1.80
Q1 2020 22.49 20.89 1.52
Q2 2020 25.77 23.99 1.79
Q3 2020 30.69 28.61 2.11
Q4 2020 39.35 39.35 2.62
Q1 2021 44.44 58.50 2.60
Q2 2021 54.85 74.08 2.88
Q3 2021 77.28 More than 100 2.75
Q4 2021 More than 100 More than 100 2.32

Business Segments (Million)

Compared With The
Period Inpatient clinics Outpatient clinics Pharmacy Sales Others
Q1 2014 207.07 85.01 64.94 2.16
Q2 2014 200.50 77.40 66.66 2.51
Q1 2015 224.99 91.95 70.24 4.46
Q2 2015 211.41 86.64 70.30 3.65
Q3 2015 200.38 85.53 63.54 2.76
Q4 2015 220.47 119.55 72.94 5.72
Q1 2016 241.22 100.20 73.04 7.06
Q2 2016 229.99 99.85 72.93 7.31
Q3 2016 224.32 89.88 62.16 2.72
Q4 2016 220.91 107.73 72.64 3.69
Q1 2017 242.80 104.89 71.94 4.27
Q2 2017 224.48 92.89 70.77 3.54
Q3 2017 133.39 85.39 60.16 3.27
Q4 2017 172.44 114.51 71.35 6.30
Q1 2018 214.32 109.10 68.50 3.20
Q2 2018 188.62 79.63 76.10 1.78
Q3 2018 184.16 98.93 53.64 2.04
Q4 2018 147.36 97.71 61.91 3.70
Q1 2019 181.07 97.28 67.29 4.54
Q2 2019 185.66 95.13 68.96 3.44
Q3 2019 223.51 95.92 64.81 2.51
Q4 2019 222.02 111.18 69.80 3.51
Q1 2020 264.27 98.09 71.34 2.60
Q2 2020 238.16 70.59 61.71 2.81
Q3 2020 301.73 111.20 76.35 2.85
Q4 2020 281.15 110.99 74.56 3.81
Q1 2021 236.94 115.00 61.88 4.54
Q2 2021 284.69 102.17 67.31 2.40
Q3 2021 292.19 139.00 61.71 5.83
Q4 2021 284.48 135.06 74.52 4.89

Analysts Estimates (Million)

Item Q4 2021 (e) Q4 2021 (a) Change‬
Average 21.25 (18.39) (186.6 %)

Estimates vs Actual (Million)

Item Q4 2021 (e) Q4 2021 (a) Change
SNB Capital 23.00 (18.39) (180.0) %
AlJazira Capital 19.50 (18.39) (194.3) %

Current
Market Cap (M Riyal) 7,897.03
Enterprise Value (EV) (M) 10,232.60
Shares Outstanding ((M)) 92.04
EPS ( Riyal) (TTM) 1.98
Book Value (BV) ( Riyal) 17.08
Par Value ( Riyal) 10.00
Adjusted P/E (Last12) 43.39
P/E (TTM) 43.39
Price/book 5.02
Return on Average Assets (%) (TTM) 3.8
Return on Average Equity (%) (TTM) 12.2

Share Price

Middle East Healthcare Co. (SAUDI GERMAN HEALTH)


Comments {{getCommentCount()}}

Be the first to comment

{{Comments.indexOf(comment)+1}}
{{comment.FollowersCount}}
{{comment.CommenterComments}}
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.